Actively Recruiting
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
Led by Navy Medical Center San Diego · Updated on 2024-08-15
80
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo. Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.
CONDITIONS
Official Title
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chronic inflammatory pain lasting more than 3 months
- Pain intensity of 5 or higher on a 10-point scale
- Pain not improved by other conservative treatments such as rest, ice, compression, or oral medications
You will not qualify if you...
- Severe allergy to any specific food such as nuts, eggs, or soy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Naval Medical Center San Diego
San Diego, California, United States, 92118
Actively Recruiting
Research Team
B
Brian McLean Pain Physician, MD
CONTACT
I
IRB Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here